Literature DB >> 24689813

The association of glutathione S-transferase polymorphisms in patients with osteosarcoma: evidence from a meta-analysis.

Z Wang1, H Xu, M He, H Wu, Y Zhu, Z Su.   

Abstract

Osteosarcoma is a life-threatening malignancy that often occurs in teenagers. Numerous studies have reported glutathione S-transferase polymorphisms are associated with osteosarcoma, but the results are inconclusive, partially because the sample size in each of published studies is relatively small. Therefore, we performed a meta-analysis of the published studies to estimate the association more accurately. To preciously examine the association between the glutathione S-transferase polymorphisms and osteosarcoma, we undertook a meta-analysis of six case-control studies. The association between the glutathione S-transferase polymorphisms and osteosarcoma risk was assessed by odds ratios together with their 95% confidence intervals using a fixed-effects model or random-effects model. In addition, hazard ratio was used to measure the relationship between glutathione S-transferase polymorphisms and prognosis in patients with osteosarcoma. We found that there was significant association between the polymorphisms in GSTT1 or GSTM3 (AA versus BB) and osteosarcoma risk. In addition, there is no evidence of association on GSTM1, GSTT1, GSTP1 (IIe/IIe versus IIe/Val) or GSTP1 (IIe/IIe versus Val/Val) polymorphisms with prognosis in osteosarcoma. In conclusion, the GSTT1 and GSTM3 polymorphisms might influence osteosarcoma risk.
© 2014 John Wiley & Sons Ltd.

Entities:  

Keywords:  glutathione S-transferase; meta-analysis; osteosarcoma; polymorphism; prognosis; susceptibility

Mesh:

Substances:

Year:  2014        PMID: 24689813     DOI: 10.1111/ecc.12197

Source DB:  PubMed          Journal:  Eur J Cancer Care (Engl)        ISSN: 0961-5423            Impact factor:   2.520


  7 in total

Review 1.  Association of genetic polymorphisms with osteosarcoma risk: a meta-analysis.

Authors:  Zhenyu Bian; Qifang He; Xuepeng Wang; Maoqiang Li; Liulong Zhu
Journal:  Int J Clin Exp Med       Date:  2015-06-15

2.  Novel application of single-cell next-generation sequencing for determination of intratumoral heterogeneity of canine osteosarcoma cell lines.

Authors:  Jordan Ayers; Rowan J Milner; Galaxia Cortés-Hinojosa; Alberto Riva; Sandra Bechtel; Bikash Sahay; Matthew Cascio; Amandine Lejeune; Keijiro Shiomitsu; Carlos Souza; Oscar Hernandez; Marc Salute
Journal:  J Vet Diagn Invest       Date:  2021-01-15       Impact factor: 1.279

Review 3.  Pharmacogenomics and Pharmacogenetics in Osteosarcoma: Translational Studies and Clinical Impact.

Authors:  Claudia Maria Hattinger; Maria Pia Patrizio; Silvia Luppi; Massimo Serra
Journal:  Int J Mol Sci       Date:  2020-06-30       Impact factor: 5.923

Review 4.  Systematic meta-analysis of genetic variants associated with osteosarcoma susceptibility.

Authors:  Xinjia Wang; Zhenyu Liu
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

5.  Association of GSTM1, GSTT1, GSTM3, and GSTP1 Genes Polymorphisms with Susceptibility to Osteosarcoma: a Case- Control Study and Meta-Analysis

Authors:  Mansour Moghimi; Mohammad Reza Sobhan; Mohammad Hossein Jarahzadeh; Majid Morovati-Sharifabad; Kazem Aghili; Hossein Ahrar; Masoud Zare-Shehneh; Hossein Neamatzadeh
Journal:  Asian Pac J Cancer Prev       Date:  2019-03-26

Review 6.  Mechanisms of Resistance to Conventional Therapies for Osteosarcoma.

Authors:  Louise Marchandet; Morgane Lallier; Céline Charrier; Marc Baud'huin; Benjamin Ory; François Lamoureux
Journal:  Cancers (Basel)       Date:  2021-02-08       Impact factor: 6.639

7.  Exercise improves choroid plexus epithelial cells metabolism to prevent glial cell-associated neurodegeneration.

Authors:  Yisheng Chen; Zhiwen Luo; Yaying Sun; Fangqi Li; Zhihua Han; Beijie Qi; Jinrong Lin; Wei-Wei Lin; Mengxuan Yao; Xueran Kang; Jiebin Huang; Chenyu Sun; Chenting Ying; Chenyang Guo; Yuzhen Xu; Jiwu Chen; Shiyi Chen
Journal:  Front Pharmacol       Date:  2022-09-16       Impact factor: 5.988

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.